Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients

References

• Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: a comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84(3):251–12. doi:10.4103/ijdvl.IJDVL_1021_16.
   PubMed Web of Science ®Google Scholar
• Johnson R, McElhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis. 2007;11(Suppl 2):S43–48. doi:10.1016/s1201-9712(07)60021-6.
   PubMedGoogle Scholar
• van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714–1732. doi:10.1080/21645515.2020.1847582.
   PubMed Web of Science ®Google Scholar
• Marra F, Chong M, Najafzadeh M. Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infect Dis. 2016;16(1):589. doi:10.1186/s12879-016-1898-z.
   PubMedGoogle Scholar
• Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4(3):238–245. doi:10.4161/hv.4.3.5686.
   PubMed Web of Science ®Google Scholar
• Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Bénard É, Brisson M. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. Can Med Assoc J. 2019;191(34):E932–939. doi:10.1503/cmaj.190274.
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization. Updated Recommendations on the Use of Herpes Zoster Vaccines; 2018. [accessed 2023 March]. https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.
   Google Scholar
• McGirr A, Bourgoin T, Wortzman M, Millson B, McNeil SA. An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: a retrospective database study. Vaccine. 2021;39(25):3397–3403. doi:10.1016/j.vaccine.2021.04.053.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Part 1 - key immunization information. Timing of vaccine administration: Canadian immunization guide [Internet]. Ottawa (ON): Government of Canada; 2017 May. [accessed 2023 November]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html.
   Google Scholar
• Baalbaki NA, Fava JP, Ng M, Okorafor E, Nawaz A, Chiu W, Salim A, Cha R, Kilgore PE. A community-based survey to assess knowledge, attitudes, beliefs and practices regarding herpes zoster in an urban setting. Infect Dis Ther. 2019;8(4):687–694. doi:10.1007/s40121-019-00269-2.
   PubMed Web of Science ®Google Scholar
• Bricout H, Torcel-Pagnon L, Lecomte C, Almas MF, Matthews I, Lu X, Wheelock A, Sevdalis N. Determinants of shingles vaccine acceptance in the United Kingdom. PLoS One. 2019;14(8):e0220230. doi:10.1371/journal.pone.0220230.
   PubMed Web of Science ®Google Scholar
• Del Signore C, Hemmendinger A, Khanafer N, Thierry J, Trépo E, Martin Gaujard G, Chapurlat R, Elias C, Vanhems P. Acceptability and perception of the herpes zoster vaccine in the 65 and over population: a French observational study. Vaccine. 2020;38(37):5891–5895. doi:10.1016/j.vaccine.2020.07.004.
   PubMed Web of Science ®Google Scholar
• Valente N, Lupi S, Stefanati A, Cova M, Sulcaj N, Piccinni L, Gabutti G, GPs Study Group. Evaluation of the acceptability of a vaccine against herpes zoster in the over 50 years old: an Italian observational study. BMJ Open. 2016;6(10):e011539. doi:10.1136/bmjopen-2016-011539.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang L, Li L, Liu C, Jin H, Lin L. Willingness to vaccinate against herpes zoster and its associated factors across WHO regions: global systematic review and meta-analysis. JMIR Public Health Surveill. 2023;9:e43893. doi:10.2196/43893.
   PubMedGoogle Scholar
• LaMori J, Feng X, Pericone CD, Mesa-Frias M, Sogbetun O, Kulczycki A. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017–2021. Vaccine. 2022;40(15):2266–2273. doi:10.1016/j.vaccine.2022.03.006.
   PubMed Web of Science ®Google Scholar
• Shuvo S, Hagemann T, Hohmeier K, Chiu CY, Ramachandran S, Gatwood J. The role of social determinants in timely herpes zoster vaccination among older American adults. Hum Vaccin Immunother. 2021;17(7):2043–2049. doi:10.1080/21645515.2020.1856598.
   PubMed Web of Science ®Google Scholar
• Vogelsang EM, Polonijo AN. Scarier than the flu shot?: the social determinants of shingles and influenza vaccinations among U.S. older adults. Vaccine. 2022;40(47):6747–6755. doi:10.1016/j.vaccine.2022.09.061.
   PubMedGoogle Scholar
• Lu PJ, O’Halloran A, Williams WW, Harpaz R. National and state-specific shingles vaccination among adults aged ≥60 years. Am J Prev Med. 2017;52(3):362–372. doi:10.1016/j.amepre.2016.08.031.
   PubMed Web of Science ®Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101. doi:10.1191/1478088706qp063oa.
   Google Scholar
• Brooks J, McCluskey S, Turley E, King N. The utility of template analysis in qualitative psychology research. Qual Res Psychol. 2015;12(2):202–222. doi:10.1080/14780887.2014.955224.
   PubMed Web of Science ®Google Scholar
• Fix J, Vielot NA, Lund JL, Weber DJ, Smith JS, Hudgens MG, Becker-Dreps S. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50–64 years old in the United States. Vaccine. 2023;41(1):49–60. doi:10.1016/j.vaccine.2022.10.076.
   PubMed Web of Science ®Google Scholar
• Patterson BJ, Chen C-C, McGuiness CB, Ma S, Glasser LI, Sun K, Buck PO. Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: a retrospective pharmacy and medical claims analysis. J Am Pharm Assoc. 2022;62(2):526–536.e510. doi:10.1016/j.japh.2021.11.010.
   Google Scholar
• Leung J, Gray EB, Anderson TC, Sharkey SM, Dooling K. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50–64 years in the United States. Vaccine. 2022;40(50):7187–7190. doi:10.1016/j.vaccine.2022.10.065.
   PubMed Web of Science ®Google Scholar
• Funovits AL, Wagamon KL, Mostow EN, Brodell RT. Refusal of shingles vaccine: implications for public health. J Am Acad Dermatol. 2012;66(6):1011–1012. doi:10.1016/j.jaad.2011.11.931.
   PubMed Web of Science ®Google Scholar
• Steben M, Durand N, Guichon JR, Greenwald ZR, McFaul S, Blake J. A national survey of Canadian physicians on HPV: knowledge, barriers, and preventive practices. J Obstet Gynaecol Can. 2019;41(5):599–607.e593. doi:10.1016/j.jogc.2018.09.016.
   PubMed Web of Science ®Google Scholar
• Abbas KM, Kang GJ, Chen D, Werre SR, Marathe A. Demographics, perceptions, and socioeconomic factors affecting influenza vaccination among adults in the United States. PeerJ. 2018;6:e5171. doi:10.7717/peerj.5171.
   PubMed Web of Science ®Google Scholar
• Eid DD, Meagher RC, Lengel AJ. The impact of pharmacist interventions on herpes zoster vaccination rates. Consult Pharm®. 2015;30(8):459–462. doi:10.4140/TCP.n.2015.459.
   PubMedGoogle Scholar
• Opstelten W, van Essen GA, Hak E. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine. 2009;27(2):192–196. doi:10.1016/j.vaccine.2008.10.047.
   PubMed Web of Science ®Google Scholar
• Teeter BS, Garza KB, Stevenson TL, Williamson MA, Zeek ML, Westrick SC. Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies. Vaccine. 2014;32(43):5749–5754. doi:10.1016/j.vaccine.2014.08.040.
   PubMed Web of Science ®Google Scholar
• Gatwood J, Brookhart A, Kinney O, Hagemann T, Chiu CY, Ramachandran S, Hohmeier KC. Clinical nudge impact on herpes zoster vaccine series completion in pharmacies. Am J Preventive Med. 2022;63:582–591. doi:10.1016/j.amepre.2022.04.018.
   PubMed Web of Science ®Google Scholar
• Tyler R, Kile S, Strain O, Kennedy CA, Foster KT. Impact of pharmacist intervention on completion of recombinant zoster vaccine series in a community pharmacy. J Am Pharm Assoc. 2021;61(4s):S12–16. doi:10.1016/j.japh.2020.09.010.
   Google Scholar
• Canadian Pharmacists Association. Injection authority and vaccine administration in pharmacies across Canada. https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/InjectionVaccinationScan_Feb2024_EN.pdf. 2022. Accessed January 2023.
   Google Scholar
• Public Health Agency of Canada. Timing of vaccine administration: Canadian immunization guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html. 2020. Accessed March 2023.
   Google Scholar
• Bardosh K, de Figueiredo A, Gur-Arie R, Jamrozik E, Doidge J, Lemmens T, Keshavjee S, Graham JE, Baral S. The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. BMJ Glob Health. 2022;7(5):e008684. doi:10.1136/bmjgh-2022-008684.
   PubMed Web of Science ®Google Scholar